Stocks and Investing
Stocks and Investing
Tue, July 13, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Judah Frommer Initiated (ATAI) at Buy and Held Target at $25 on, Jul 13th, 2021
Judah Frommer of Credit Suisse, Initiated "Atai Life Sciences N.V." (ATAI) at Buy and Held Target at $25 on, Jul 13th, 2021.
Judah has made no other calls on ATAI in the last 4 months.
There is 1 other peer that has a rating on ATAI. Out of the 1 peers that are also analyzing ATAI, 0 agree with Judah's Rating of Hold.
This is the rating of the analyst that currently disagrees with Judah
- Nathan Weinstein of "Aegis Capital" Initiated at Strong Buy and Held Target at $26 on, Thursday, July 8th, 2021
Contributing Sources